Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO) (INDIGO)

Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)

Efficacite et Innocuite du Tannate de Gelatine Dans le Traitement de la Diarrhee aiguë de l'Enfant. Une Etude Randomisee, Controlee, en Double Aveugle (INDIGO)

To evaluate the safety, global efficacy and rapidity of action of GT in children with acute gastroenteritis taking ORS solution.

Study purpose: To evaluate the safety, global efficacy and rapidity of action of GT in children with acute gastroenteritis taking ORS solution. Study centers/ settings: The recruitment will take place in public health facilities in Senegal. Proposed site is the Niakhar Center IRD BP 1386 Hann Mariste, Dakar-Senegal) with the health center of Niakhar as satellite site. More sites can be opened at the discretion of the Sponsor if required Study design and type: Interventional, randomized, controlled, double blind, multicenter phase III clinical trial. Test product/arms: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation versus (vs.) placebo + ORS + Zinc supplementation. Investigational Product: GELATIN TANNATE (GT): Children below 3 years of age: One sachet every 6 hours Children from 3 to 14 years of age: 2 sachets every 6 hours. All patients will take ORS solution according to 2014 European recommendations, and Zinc supplementation. Reference Product: Placebo. The dose regimen and mode of administration will be similar as the investigational product. Number of patients planned: 150 patients, randomized in 1:1 basis (75 in each arm). Inclusion criteria: Children eligible for the trial must fulfil ALL of the following criteria: AGE defined as a change in stool consistency to loose or liquid form (according to the Bristol Stool Form (BSF) scale ≥ 6 or, the Brussels Infant and Toddler Stool Scale (BITSS) =4 in the case of infants ≤ 3 years (see Annex 1) and/or an increase in the frequency of evacuations (typically ≥3 in 24 h), AGE lasting between 1 day and 2 days; Children from 3 months old Children up to 14 years old; Written informed consent form signed by parents or legal guardians must be provided to caregivers. Subject willing and able to comply with study restrictions and willing to return to the health center and to perform the follow-up evaluation as specified in the protocol. Non-inclusion criteria: In order to participate in this study, all subjects must meet NONE of the following exclusion criteria: Use of antibiotics, diosmectite, probiotics, racecadotril, loperamide or zinc (including zinc containing ORS) within a week prior to enrolment Chronic diarrheal gastrointestinal disease (eg, inflammatory bowel diseases, cystic fibrosis, coeliac disease, food allergy) Immunodeficiencies Signs of malnutrition according to the opinion of the investigator (weight/height under 3rd z score as per World Health Organization [WHO] Child Growth Standards) Subject who previously entered in a clinical study within the past 30 days. Pregnancy and suspected Pregnancy Study duration: 7 days including 5 days of treatment; follow up at Day 7. Study outcomes: Primary outcome: The primary outcome will be the duration of diarrhea, defined as the time between start of diarrhea and the normalization of stool consistency according to the BSF or BITSS (in BSF scale, =3 or =4; in BITSS, =2), or/and the time until the normalization of the number of stools (compared with the period before the onset of diarrhea), and the presence of normal stools for 48 h. A subgroup analysis will be performed with patients for whom the cause of the diarrhea is not parasitic. Secondary outcomes: Stool Decrease Index (SDI) Time resolution of diarrhea from start of treatment Need for intravenous rehydration Number of watery stools per day Vomiting Weight gain Recurrence of diarrhea (48 h after intervention) Severity of diarrhea according to Vesikari scale Use of concomitant medications. Adverse events (AEs) Expected results: Significant decrease of duration of diarrhea with the Gelatin Tannate plus ORS plus zinc than placebo+ ORS +zinc

Duration of diarrhea, defined as the time between start of diarrhea and the normalization of stool consistency according to the BSF or BITSS (in BSF scale, =3 or =4; in BITSS, =2), or/and the time until the normalization of the number of stools (compared with the period before the onset of diarrhea), and the presence of normal stools for 48 h.

Inclusion Criteria: AGE defined as a change in stool consistency to loose or liquid form (according to the Bristol Stool Form (BSF) scale ≥ 6 or, the Brussels Infant and Toddler Stool Scale (BITSS) =4 in the case of infants ≤ 3 years (see Annex 1) and/or an increase in the frequency of evacuations (typically ≥3 in 24 h), AGE lasting between 1 day and 2 days; Children from 3 months old Children up to 14 years old; Written informed consent form signed by parents or legal guardians must be provided to caregivers. Subject willing and able to comply with study restrictions and willing to return to the health center and to perform the follow-up evaluation as specified in the protocol. Exclusion Criteria: Use of antibiotics, diosmectite, probiotics, racecadotril, loperamide or zinc (including zinc containing ORS) within a week prior to enrolment Chronic diarrheal gastrointestinal disease (e.g, inflammatory bowel diseases, cystic fibrosis, coeliac disease, food allergy) Immunodeficiencies Signs of malnutrition according to the opinion of the investigator (weight/height under 3rd z score as per World Health Organization [WHO] Child Growth Standards) Need for Intravenous rehydration Subject who previously entered in a clinical study within the past 30 days. Pregnancy and suspected Pregnancy